Logo

Celltrion Reports Results of CT-P39 (biosimilar, omalizumab) in P-I Study for Asthma and Chronic Idiopathic Urticaria

Share this
Celltrion Reports Results of CT-P39 (biosimilar, omalizumab) in P-I Study for Asthma and Chronic Idiopathic Urticaria

Celltrion Reports Results of CT-P39 (biosimilar, omalizumab) in P-I Study for Asthma and Chronic Idiopathic Urticaria

Shots:

  • The company reported the results from the P-I study to evaluates omalizumab biosimilar CT-P39 vs Genentech’ Xolair in 176 healthy patients aged b/w 18 & 55yrs. with asthma & CIU. The therapy was given as 150mg dose of CT-P39, EU & US-Xolair
  • The results showed similar safety & PK profiles to Xolair, 62 patients received biosimilar, 64 received the EU-Xolair & 50 US-Xolair, mean serum concentrations were similar b/w the treatment groups
  • The company has launched omalizumab biosimilar Genolar in Russia in Feb 2022 for persistent atopic bronchial asthma & resistant CIU aged ≥6yrs. under the agreement b/w selexis & generium. Omalizumab is an anti-inflammatory agent that binds to free IgE resulting in a reduction of free IgE & increase in total IgE

Ref: Center For Biosimilars | Image: Linkedin

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions